Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 58

Sort by

Sort Order Select

Journal Articles

Psychometric Validation and Meaningful Change Threshold Determination of EORTC QLQ-C30 Physical Functioning and Promis SF v1.0-Fatigue 7a Functional Domain in Patients with High-Risk Myelodysplastic Syndromes Treated with Venetoclax and Azacitidine

Roger M. Lyons, Brandon Foster, Adrian Jewett, Liu Liu, Rohini Sen, Cat N. Bui, Rajesh Kamalakar, Jalaja Potluri

Blood (2023) 142 (Supplement 1): 6472.

https://doi.org/10.1182/blood-2023-178011

Published: 2023

Journal Articles

Progression to Myelofibrosis in Patients with Essential Thrombocythemia: A Real-World Analysis from the Prospective MOST Study

Abdulraheem Yacoub, Roger M. Lyons, Evan M. Braunstein, JE Hamer-Maansson, Tricia Kalafut, Ruben A. Mesa

Blood (2023) 142 (Supplement 1): 2433.

https://doi.org/10.1182/blood-2023-180240

Published: 2023

Journal Articles

Sabatolimab in Combination with Hypomethylating Agents (HMAs) Was Safe in Patients (Pts) with Intermediate-, High-, or Very-High-Risk Myelodysplastic Syndrome (MDS)

Guillermo Garcia-Manero, Roger M. Lyons, Savita Nandal, Mushtaq Ashraf, Ramarao Thellaboina, Julie Ruckel-Kumar, Hans D. Menssen, Amer M. Zeidan

Blood (2023) 142 (Supplement 1): 4606.

https://doi.org/10.1182/blood-2023-186490

Published: 2023

Journal Articles

In -Class Transition ( i CT) from Parenteral Bortezomib (V) to Oral Ixazomib Therapy in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) in the Community-Based US MM-6 Study: Subanalysis of Randomized Controlled Trial (RCT)-Ineligible and RCT-Eligible Pts

Saulius K. Girnius, Joshua Richter, Kimberly Bogard, Habte A. Yimer, Sudhir Manda, Roger M. Lyons, Stephen J. Noga, Robert M. Rifkin

Blood (2023) 142 (Supplement 1): 6677.

https://doi.org/10.1182/blood-2023-179795

Published: 2023

Journal Articles

In -Class Transition ( i CT) from Parenteral Bortezomib to Oral Ixazomib Therapy in Newly Diagnosed Multiple Myeloma (NDMM) Patients from the Community-Based US MM-6 Study: Subgroup Analyses of the Fully Accrued Dataset in Patients Aged <75 and ≥75 Years

Ruemu E. Birhiray, Robert M. Rifkin, Christopher A. Yasenchak, January Fields-Meehan, Roger M. Lyons, Ramalingham Ratnasabapathy, Kimberly Bogard, Kim Tran, Dasha Cherepanov, Stephen J. Noga, Saulius K. Girnius, Stephen J. Noga

Blood (2022) 140 (Supplement 1): 7322–7323.

https://doi.org/10.1182/blood-2022-163071

Published: 2022

Journal Articles

Treatment Patterns and Overall Survival (OS) Among Patients with Myelodysplastic Syndromes (MDS) Treated in the US Community Oncology Setting: A Real-World Retrospective Observational Study

Roger M. Lyons, Wei-Han Cheng, Laura Moore-Schiltz, Ping Shi, Anders Svensson, Cat N. Bui, Jessica E. Hutti, Ann Marie McNeill, Elizabeth S. Mearns, Archibong Yellow-Duke, Ira Zackon

Blood (2022) 140 (Supplement 1): 6938–6939.

https://doi.org/10.1182/blood-2022-163098

Published: 2022

Journal Articles

Stimulus MDS-US Trial in Progress: Evaluating Sabatolimab in Combination with Hypomethylating Agents (HMAs) in Patients with Intermediate-, High-, or Very High-Risk Myelodysplastic Syndrome (MDS)

Amer M. Zeidan, Amy E. DeZern, Uma Borate, Krissy Kobata, Susan E. Ide, John Sabo, Pedro Marques Ramos, Haiying Sun, Roger M. Lyons, Guillermo Garcia-Manero

Blood (2022) 140 (Supplement 1): 4069–4070.

https://doi.org/10.1182/blood-2022-167259

Published: 2022

Journal Articles

Characteristics, Blood Counts, Treatments, and Clinical Outcomes of 5871 Patients with Polycythemia Vera Treated in US Community Practices

Roger M. Lyons, Kathleen M. Aguilar, Lavanya Sudharshan, Divea Venkatasetty, Juliet Ndukum, Ira Zackon, Jingbo Yu

Blood (2022) 140 (Supplement 1): 13310–13311.

https://doi.org/10.1182/blood-2022-163416

Published: 2022

Journal Articles

In -Class Transition ( i CT) from Parenteral Bortezomib to Oral Ixazomib Proteasome Inhibitor (PI) Therapy Increases the Feasibility of Long-Term PI Treatment and Benefit for Newly Diagnosed Multiple Myeloma (NDMM) Patients in an Outpatient Setting: Updated Real-World Results from the Community-Based United States (US) MM-6 Study

Saulius K. Girnius, MD, Habte A. Yimer, MD, Stephen J. Noga, MDPhD, Sudhir Manda, MD, Roger M. Lyons, MD, Kimberly Bogard, PharmD, Presley Whidden, Dasha Cherepanov, Vickie Lu, PhD, Jack Aiello, EE, MS, BS, Joshua R. Richter, MD, Robert M. Rifkin, MD

Blood (2020) 136 (Supplement 1): 2–4.

https://doi.org/10.1182/blood-2020-140482

Published: 2020

Journal Articles

Tapering Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia: Recommendations Based on the RAND/UCLA Modified Delphi Panel Method

Adam Cuker, MD, Jenny M. Despotovic, DO, Rachael F. Grace, MD, Caroline Kruse, Michele P. Lambert, MD MSTR, Howard Liebman, MD, Roger M. Lyons, MD, Keith R McCrae, MD, Vinod A. Pullarkat, MD, Jeffrey Wasser, MD, David Beenhouwer, MD, Sarah N Gibbs, MPH, Irina Yermilov, MD MPH, MS, Michael S Broder, MD MSHS

Blood (2020) 136 (Supplement 1): 6–8.

https://doi.org/10.1182/blood-2020-133262

Published: 2020

Journal Articles

Long-Term Proteasome Inhibitor (PI) Therapy in Community Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (Btz)-Based to Ixazomib-Based Induction: Results from the US MM-6 Study in the Real World (RW) Setting

Robert M. Rifkin, MD, Sudhir Manda, MD, Stephen J Noga, MD PhD, Habte A Yimer, MD, Saulius K. Girnius, MD, Ruemu Ejedafeta Birhiray, MD, Christopher A. Yasenchak, MD, Roger M. Lyons, MD, Presley Whidden, Robert L. Schlossman, MD, Bingxia Wang, PhD, Ralph V. Boccia, MD

Blood (2019) 134 (Supplement_1): 1882.

https://doi.org/10.1182/blood-2019-124747

Published: 2019

Journal Articles

Disease and Clinical Characteristics of Patients with Myelofibrosis Enrolled in the MOST Study

Aaron T. Gerds, MD MS, Roger M. Lyons, MD, Philomena Colucci, DO, MS, Patricia Kalafut, PhD, Dilan Paranagama, PhD, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 4190.

https://doi.org/10.1182/blood-2019-122441

Published: 2019

Journal Articles

Real-World (RW) Treatment Patterns and Patient-Related Factors Including Quality of Life (QoL), Medication Adherence, and Actigraphy in Community Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (btz) to Ixazomib: The US MM-6 Community-Based Study

Stephen J Noga, MD PhD, Robert M. Rifkin, MD, Sudhir Manda, MD, Ruemu Ejedafeta Birhiray, MD, Roger M. Lyons, MD, Presley Whidden, Robert L. Schlossman, MD, Bingxia Wang, PhD, Ralph V. Boccia, MD

Blood (2019) 134 (Supplement_1): 3168.

https://doi.org/10.1182/blood-2019-124784

Published: 2019

Journal Articles

Disease and Clinical Characteristics of Patients with Essential Thrombocythemia Enrolled in the MOST Study

Abdulraheem Yacoub, MD, Roger M. Lyons, MD, Srdan Verstovsek, MD PhD, Ryan Shao, MD, David Tin Chu, MD, Apurv Agrawal, MD, Smitha Sivaraman, PhD, Philomena Colucci, DO, MS, Peter Yao, John Mascarenhas, MD

Blood (2018) 132 (Supplement 1): 4306.

https://doi.org/10.1182/blood-2018-99-112183

Published: 2018

Journal Articles

Evaluating the Efficacy, Safety, and Dose Dependent Activities of Entospletinib in Patients with Chronic Lymphocytic Leukemia

Jeffrey P. Sharman, MD, Kathryn S. Kolibaba, MD, Jose Azar, MD, Rama Balaraman, MD, Roger M. Lyons, MD, Mitchell R. Smith, MD PhD, Esteban Abella-Dominicis, MD, Wei Ye, PhD, Wen Shi, MD PhD, Thomas Giever, DO, Andres Forero-Torres, MD

Blood (2017) 130 (Supplement 1): 832.

https://doi.org/10.1182/blood.V130.Suppl_1.832.832

Published: 2017

Journal Articles

Efficacy and Safety of Ofatumumab and Bendamustine Followed By Ofatumumab Maintenance in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma after Prior Rituximab

Kathryn S. Kolibaba, MD, Mikhail Shtivelband, MD PhD, Edwin C. Kingsley, MD, Mehdi M. Moezi, MD, Donald Richards, MD PhD, Jeffrey P. Sharman, MD, Feng Xiaoshu, MS, Megan Cannan, B.S, Rafik Fellague-Chebra, MD, Roger M. Lyons, MD

Blood (2017) 130 (Supplement 1): 1500.

https://doi.org/10.1182/blood.V130.Suppl_1.1500.1500

Published: 2017

Journal Articles

CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma

James R. Berenson, Alan Cartmell, Alberto Bessudo, Roger M. Lyons, Wael Harb, Dimitrios Tzachanis, Richy Agajanian, Ralph Boccia, Morton Coleman, Robert A. Moss, Robert M. Rifkin, Priti Patel, Sandra Dixon, Ying Ou, Janet Anderl, Sanjay Aggarwal, Jesus G. Berdeja

Blood (2016) 127 (26): 3360–3368.

https://doi.org/10.1182/blood-2015-11-683854

Published: 2016

Includes: Supplemental data

Journal Articles

A Randomized, Placebo-Controlled, Phase II Study of Pracinostat in Combination with Azacitidine (AZA) in Patients with Previously Untreated Myelodysplastic Syndrome (MDS)

Guillermo Garcia-Manero, MD, Jesus G. Berdeja, MD, Rami S. Komrokji, MD, James Essell, MD, Roger M. Lyons, MD, Michael Maris, MD, Amy E. DeZern, MD MHS, Mikkael A. Sekeres, MD MS, Gail J Roboz, MD

Blood (2015) 126 (23): 911.

https://doi.org/10.1182/blood.V126.23.911.911

Published: 2015

Journal Articles

Final Results of Anagrelide Controlled-Release (GALE-401) Safety, Efficacy and Pharmacokinetics in Subjects with Myeloproliferative Neoplasms (MPN)-Related Thrombocytosis

Phu V. Troung, MD F.A.C.P., Marc Saltzman, MD, Alberto Bessudo, MD, William Jawien, MD, Roger M. Lyons, MD F.A.C.P., Dmitriy Berenzon, MD, Raul Mena, MD, Nasiema Wingate-Pearse, Olivier Barriere, PhD, Hali E. Beeson, Paul F. Glidden, PhD, Gavin S. Choy, PharmD, MBA, Srdan Verstovsek, MD PhD

Blood (2015) 126 (23): 4074.

https://doi.org/10.1182/blood.V126.23.4074.4074

Published: 2015

Journal Articles

Relationship Between Chelation and Clinical Outcomes in Lower-Risk Patients with Myelodysplastic Syndrome (MDS): Registry Analysis at 5 Years

Roger M. Lyons, MD, Billie J. Marek, MD, Carole Paley, MD, Jason Esposito, MSHS, Katie McNamara, MSHS, CCRA, Lawrence Garbo, MD, Nicholas DiBella, MD, Guillermo Garcia-Manero, MD

Blood (2014) 124 (21): 1350.

https://doi.org/10.1182/blood.V124.21.1350.1350

Published: 2014

NARROW

Psychometric Validation and Meaningful Change Threshold Determination of EORTC QLQ-C30 Physical Functioning and Promis SF v1.0-Fatigue 7a Functional Domain in Patients with High-Risk Myelodysplastic Syndromes Treated with Venetoclax and Azacitidine

Progression to Myelofibrosis in Patients with Essential Thrombocythemia: A Real-World Analysis from the Prospective MOST Study

Sabatolimab in Combination with Hypomethylating Agents (HMAs) Was Safe in Patients (Pts) with Intermediate-, High-, or Very-High-Risk Myelodysplastic Syndrome (MDS)

In -Class Transition ( i CT) from Parenteral Bortezomib (V) to Oral Ixazomib Therapy in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) in the Community-Based US MM-6 Study: Subanalysis of Randomized Controlled Trial (RCT)-Ineligible and RCT-Eligible Pts

In -Class Transition ( i CT) from Parenteral Bortezomib to Oral Ixazomib Therapy in Newly Diagnosed Multiple Myeloma (NDMM) Patients from the Community-Based US MM-6 Study: Subgroup Analyses of the Fully Accrued Dataset in Patients Aged <75 and ≥75 Years

Treatment Patterns and Overall Survival (OS) Among Patients with Myelodysplastic Syndromes (MDS) Treated in the US Community Oncology Setting: A Real-World Retrospective Observational Study

Stimulus MDS-US Trial in Progress: Evaluating Sabatolimab in Combination with Hypomethylating Agents (HMAs) in Patients with Intermediate-, High-, or Very High-Risk Myelodysplastic Syndrome (MDS)

Characteristics, Blood Counts, Treatments, and Clinical Outcomes of 5871 Patients with Polycythemia Vera Treated in US Community Practices

Tapering Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia: Recommendations Based on the RAND/UCLA Modified Delphi Panel Method

Long-Term Proteasome Inhibitor (PI) Therapy in Community Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (Btz)-Based to Ixazomib-Based Induction: Results from the US MM-6 Study in the Real World (RW) Setting

Disease and Clinical Characteristics of Patients with Myelofibrosis Enrolled in the MOST Study

Real-World (RW) Treatment Patterns and Patient-Related Factors Including Quality of Life (QoL), Medication Adherence, and Actigraphy in Community Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (btz) to Ixazomib: The US MM-6 Community-Based Study

Disease and Clinical Characteristics of Patients with Essential Thrombocythemia Enrolled in the MOST Study

Evaluating the Efficacy, Safety, and Dose Dependent Activities of Entospletinib in Patients with Chronic Lymphocytic Leukemia

Efficacy and Safety of Ofatumumab and Bendamustine Followed By Ofatumumab Maintenance in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma after Prior Rituximab

CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma

A Randomized, Placebo-Controlled, Phase II Study of Pracinostat in Combination with Azacitidine (AZA) in Patients with Previously Untreated Myelodysplastic Syndrome (MDS)

Final Results of Anagrelide Controlled-Release (GALE-401) Safety, Efficacy and Pharmacokinetics in Subjects with Myeloproliferative Neoplasms (MPN)-Related Thrombocytosis

Relationship Between Chelation and Clinical Outcomes in Lower-Risk Patients with Myelodysplastic Syndrome (MDS): Registry Analysis at 5 Years

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only